Geode Capital Management LLC Purchases 40,349 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Geode Capital Management LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,259,537 shares of the company's stock after acquiring an additional 40,349 shares during the quarter. Geode Capital Management LLC owned about 2.76% of IDEXX Laboratories worth $1,138,732,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of IDXX. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $25,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $27,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its stake in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after buying an additional 60 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at $36,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 1.7 %

IDEXX Laboratories stock traded down $7.64 during mid-day trading on Wednesday, reaching $437.08. The company's stock had a trading volume of 566,714 shares, compared to its average volume of 513,294. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The business's 50 day simple moving average is $442.37 and its 200 day simple moving average is $472.89. The company has a market capitalization of $35.79 billion, a price-to-earnings ratio of 42.19, a price-to-earnings-growth ratio of 3.98 and a beta of 1.37.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the previous year, the business earned $2.53 earnings per share. IDEXX Laboratories's quarterly revenue was up 6.6% on a year-over-year basis. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on IDXX shares. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler reissued a "neutral" rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price on the stock. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Finally, Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $539.63.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.